• 1
    Thorley-Lawson D.A., Gross A. (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350: 132837.
  • 2
    Hutt-Fletcher L.M. (2007) Epstein-Barr virus entry. J Virol 81: 782532.
  • 3
    Cohen J.I. (2000) Epstein-Barr virus infection. N Engl J Med 343: 48192.
  • 4
    Williams H., Crawford D.H. (2006) Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood 107: 8629.
  • 5
    Fox C.P., Shannon-Lowe C., Rowe M. (2011) Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations. Herpesviridae 2: 8.
  • 6
    Kimura H., Hoshino Y., Kanegane H., Tsuge I., Okamura T., Kawa K., Morishima T. (2001) Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 98: 2806.
  • 7
    Kimura H., Morishima T., Kanegane H., Ohga S., Hoshino Y., Maeda A., Imai S., Okano M., Morio T., Yokota S., Tsuchiya S., Yachie A., Imashuku S., Kawa K., Wakiguchi H. (2003) Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 187: 52733.
  • 8
    Sugaya N., Kimura H., Hara S., Hoshino Y., Kojima S., Morishima T., Tsurumi T., Kuzushima K. (2004) Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T cells in patients with chronic active EBV infection. J Infect Dis 190: 9858.
  • 9
    Kimura H., Hoshino Y., Hara S., Sugaya N., Kawada J., Shibata Y., Kojima S., Nagasaka T., Kuzushima K., Morishima T. (2005) Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. J Infect Dis 191: 5319.
  • 10
    Ohga S., Nomura A., Takada H., Ihara K., Kawakami K., Yanai F., Takahata Y., Tanaka T., Kasuga N., Hara T. (2001) Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. J Infect Dis 183: 17.
  • 11
    Cohen J.I., Jaffe E.S., Dale J.K., Pittaluga S., Heslop H.E., Rooney C.M., Gottschalk S., Bollard C.M., Rao V.K., Marques A., Burbelo P.D., Turk S.P., Fulton R., Wayne A.S., Little R.F., Cairo M.S., El-Mallawany N.K., Fowler D., Sportes C., Bishop M.R., Wilson W., Straus S.E. (2011) Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood 117: 583549.
  • 12
    Iwakura Y., Nakae S., Saijo S., Ishigame H. (2008) The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 226: 5779.
  • 13
    Kolls J.K., Linden A. (2004) Interleukin-17 family members and inflammation. Immunity 21: 46776.
  • 14
    Mckinstry K.K., Strutt T.M., Buck A., Curtis J.D., Dibble J.P., Huston G., Tighe M., Hamada H., Sell S., Dutton R.W., Swain S.L. (2009) IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol 182: 735363.
  • 15
    Kimura H. (2006) Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol 16: 25161.
  • 16
    Katano H., Ali M.A., Patera A.C., Catalfamo M., Jaffe E.S., Kimura H., Dale J.K., Straus S.E., Cohen J.I. (2004) Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. Blood 103: 124452.
  • 17
    Roark C.L., Simonian P.L., Fontenot A.P., Born W.K., O'brien R.L. (2008) Gammadelta T cells: an important source of IL-17. Curr Opinion Immunol 20: 3537.
  • 18
    Spits H., Cupedo T. (2012) Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol 30: 64775.
  • 19
    Luger D., Silver P.B., Tang J., Cua D., Chen Z., Iwakura Y., Bowman E.P., Sgambellone N.M., Chan C.C., Caspi R.R. (2008) Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 205: 799810.
  • 20
    Ivanov Ii, Mckenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., Cua D.J., Littman D.R. (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 112133.
  • 21
    Hirota K., Duarte J.H., Veldhoen M., Hornsby E., Li Y., Cua D.J., Ahlfors H., Wilhelm C., Tolaini M., Menzel U., Garefalaki A., Potocnik A.J., Stockinger B. (2011) Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 12: 25563.
  • 22
    Ohshima K., Kimura H., Yoshino T., Kim C.W., Ko Y.H., Lee S.S., Peh S.C., Chan J.K. (2008) Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int 58: 20917.